| ［1］ |
Siegel RL，Giaquinto AN，Jemal A，et al. Cancer statistics， 2024［J］.CA Cancer J Clin，2024，74（1）：12-49.
|
| ［2］ |
Fisher B，Brown A，Mamounas E，et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer： findings from National Surgical Adjuvant Breast and Bowel Project B-18［J］. J Clin Oncol， 1997， 15（7）： 2483-2493.
|
| ［3］ |
Bear HD，Anderson S，Brown A，et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide：preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27［J］. J Clin Oncol， 2003， 21（22）： 4165-4174.
|
| ［4］ |
Fisher B，Anderson S，Bryant J，et al. Twenty-year follow-up of a randomized trial comparing total mastectomy，lumpectomy，and lumpectomy plus irradiation for the treatment of invasive breast cancer［J］. N Engl J Med， 2002， 347（16）： 1233-1241.
|
| ［5］ |
EBCTCG （Early Breast Cancer Trialists' Collaborative Group），McGale P，Taylor C，et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality： meta-analysis of individual patient data for 8135 women in 22 randomised trials［J］. Lancet，2014，383（9935）：2127-2135.
|
| ［6］ |
Buchholz TA，Katz A，Strom EA，et al. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy［J］. Int J Radiat Oncol， 2002， 53（4）： 880-888.
|
| ［7］ |
Mamounas EP，Anderson SJ，Dignam JJ，et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy：results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27［J］. J Clin Oncol， 2012， 30（32）： 3960-3966.
|
| ［8］ |
Huang EH，Tucker SL，Strom EA，et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy［J］. J Clin Oncol， 2004， 22（23）： 4691-4699.
|
| ［9］ |
Liu J，Mao K，Jiang S，et al. The role of postmastectomy radiotherapy in clinically node-positive， stage Ⅱ-Ⅲ breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy： an analysis from the NCDB［J］. Oncotarget， 2016， 7（17）： 24848-24859.
|
| ［10］ |
Huang Z，Zhu L，Huang XB，et al. Postmastectomy radiation therapy based on pathologic nodal status in clinical node-positive stage Ⅱ to Ⅲ breast cancer treated with neoadjuvant chemotherapy［J］. Int J Radiat Oncol， 2020， 108（4）： 1030-1039.
|
| ［11］ |
Garg AK，Oh JL，Oswald MJ，et al. Effect of postmastectomy radiotherapy in patients <35 years old with stage Ⅱ-Ⅲ breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy［J］. Int J Radiat Oncol Biol Phys， 2007， 69（5）： 1478-1483.
|
| ［12］ |
de Wild SR，de Munck L，Simons JM，et al. De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer （RAPCHEM； BOOG 2010-03）： 5-year follow-up results of a Dutch， prospective， registry study［J］. Lancet Oncol， 2022， 23（9）： 1201-1210.
|
| ［13］ |
Mamounas E，Bandos H，White J，et al. Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy： primary outcomes of NRG oncology/NSABP B-51/RTOG 1304［J］. Cancer Res， 2024， 84（9 Suppl）： Abstract nr GS02-07.
|
| ［14］ |
Mamounas EP，Bandos H，White JR，et al. Omitting regional nodal irradiation after response to neoadjuvant chemotherapy［J］. N Engl J Med，2025，392（21）：2113-2124.
|
| ［15］ |
Gradishar WJ，Moran MS，Abraham J，et al. Breast cancer，version 3.2024，NCCN clinical practice guidelines in oncology[J]. J Natl Compr Cancer Netw， 2024，22（5）:331-357.
|
| ［16］ |
中国抗癌协会乳腺癌专业委员会，中华医学会肿瘤学分会乳腺肿瘤学组.中国抗癌协会乳腺癌诊治指南与规范（2025 年版）[J]. 中国癌症杂志，2025，34（12）：1092-1187.
|
| ［17］ |
Chen X，Xia F，Luo J，et al. Postmastectomy radiotherapy reduces locoregional and disease recurrence in patients with stage Ⅱ-Ⅲ triple-negative breast cancer treated with neoadjuvant chemotherapy and mastectomy［J］. Onco Targets Ther， 2018， 11： 1973-1980.
|
| ［18］ |
Miyashita M，Niikura N，Kumamaru H，et al. Role of postmastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer patients： a study from the Japanese breast cancer registry［J］. Ann Surg Oncol， 2019， 26（8）： 2475-2485.
|
| ［19］ |
Ohri N，Moshier E，Ho A，et al. Postmastectomy radiation in breast cancer patients with pathologically positive lymph nodes after neoadjuvant chemotherapy： usage rates and survival trends［J］. Int J Radiat Oncol Biol Phys， 2017， 99（3）： 549-559.
|
| ［20］ |
Lee J，Kim JY，Bae SJ，et al. The impact of post-mastectomy radiotherapy on survival outcomes in breast cancer patients who underwent neoadjuvant chemotherapy［J］. Cancers（Basel），2021，13（24）：6205.
|
| ［21］ |
Zhang Y，Zhang Y，Liu Z，et al. Impact of postmastectomy radiotherapy on locoregional control and disease-free survival in patients with breast cancer treated with neoadjuvant chemotherapy［J］. J Oncol， 2021， 2021： 6632635.
|
| ［22］ |
Litière S，Werutsky G，Fentiman IS，et al. Breast conserving therapy versus mastectomy for stage Ⅰ-Ⅱ breast cancer： 20 year follow-up of the EORTC 10801 phase 3 randomised trial［J］. Lancet Oncol， 2012， 13（4）： 412-419.
|
| ［23］ |
Onitilo AA，Engel JM，Stankowski RV，et al. Survival comparisons for breast conserving surgery and mastectomy revisited： community experience and the role of radiation therapy［J］. Clin Med Res， 2015， 13（2）： 65-73.
|
| ［24］ |
Mauriac L，MacGrogan G，Avril A，et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm：a unicentre randomized trial with a 124-month median follow-up［J］. Ann Oncol， 1999， 10（1）： 47-52.
|
| ［25］ |
Gwark S，Kim HJ，Kim J，et al. Survival after breast-conserving surgery compared with that after mastectomy in breast cancer patients receiving neoadjuvant chemotherapy［J］. Ann Surg Oncol， 2023， 30（5）： 2845-2853.
|
| ［26］ |
Gradishar WJ， Moran MS， Abraham J， et al. Breast Cancer， Version 3. 2024， NCCN Clinical Practice Guidelines in Oncology［J］. J Natl Compr Canc Netw，2024，22（5）：331-357.
|
| ［27］ |
Daveau C，Stevens D，Brain E，et al．Is regional lymph node irradiation necessary in stage Ⅱ to Ⅲ breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy?［J］．Int J Radiat Oncol Biol Phys，2010，78（2）：337-342.
|
| ［28］ |
Schlafstein A，Liu Y，Goyal S，et al. Regional nodal irradiation for clinically node-positive breast cancer patients with pathologic negative nodes after neoadjuvant chemotherapy［J］. Clin Breast Cancer， 2022， 22（2）： 127-135.
|
| ［29］ |
Cortazar P，Zhang L，Untch M，et al. Pathological complete response and long-term clinical benefit in breast cancer：the CTNeoBC pooled analysis［J］. Lancet，2014，384（9938）：164-172.
|
| ［30］ |
Rastogi P，Anderson SJ，Bear HD，et al. Preoperative chemotherapy：updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27［J］. J Clin Oncol，2008，26（5）：778-785.
|
| ［31］ |
McGuire SE，Gonzalez-Angulo AM，Huang EH，et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy［J］. Int J Radiat Oncol Biol Phys，2007，68（4）：1004-1009.
|
| ［32］ |
Wang Q，Zhao J，Han X，et al. Is there a role for post-mastectomy radiotherapy for T1-2N1 breast cancers with node-positive pathology after patients become node-negative pathology following neoadjuvant chemotherapy？［J］. Front Oncol，2020，10：892.
|
| ［33］ |
Mak KS，Harris JR. Radiotherapy issues after neoadjuvant chemotherapy［J］. J Natl Cancer Inst Monogr，2015，2015（51）：87-89.
|
| ［34］ |
Shim SJ，Park W，Huh SJ，et al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage Ⅱ-Ⅲ breast cancer patients with pN0：a multicenter，retrospective study （KROG 12-05）［J］. Int J Radiat Oncol， 2014， 88（1）： 65-72.
|
| ［35］ |
Dai Y，Ma S，Lan A，et al. The impact of postmastectomy radiotherapy on cT1-2N1 breast cancer patients with ypN0 after neoadjuvant chemotherapy：a retrospective study based on real-world data［J］. Discov Oncol， 2023， 14（1）： 2.
|
| ［36］ |
Tan CF，Wang J，Zhong XR，et al. Is postmastectomy radiotherapy necessary for breast cancer patients with clinically node-positive downstaging to ypN0 after neoadjuvant chemotherapy［J］. Breast Cancer Res Treat， 2024， 206（1）： 45-56.
|
| ［37］ |
Bear HD，Anderson S，Smith RE，et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer：National Surgical Adjuvant Breast and Bowel Project Protocol B-27［J］. J Clin Oncol， 2006， 24（13）： 2019-2027.
|
| ［38］ |
Ebrahim AK，Lasheen O，Mokhtar S，et al. Axillary lymph node dissection versus loco-regional radiotherapy in management of the axilla in node-negative locally advanced breast cancer post neoadjuvant chemotherapy［J］. Chirurgia （Bucur），2024，119（6）：676-686.
|
| ［39］ |
Wang Y，Ouyang Y，Cai Q. Is regional nodal radiotherapy necessary for patients with CN1 and ypN0 breast cancer after neoadjuvant chemotherapy?［J］. JAMA Oncol， 2022， 8（6）： 942.
|